INMUNE BIO INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
INMUNE BIO INC. (INMB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $769.00 thousand for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-04.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2021-08-04
- INMUNE BIO INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-06-30 was $769.00K, a 12.92% increase year-over-year.
- INMUNE BIO INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-03-31 was $899.00K, a 31.82% increase year-over-year.
- INMUNE BIO INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-09-30 was $1.05M, a 7.28% increase year-over-year.
- INMUNE BIO INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-06-30 was $681.00K, a 30.13% decline year-over-year.
- INMUNE BIO INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $3.11M, a 24.03% decline from fiscal 2019.
- INMUNE BIO INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $4.10M, a 23.79% decline from fiscal 2018.
- INMUNE BIO INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $5.38M, a 2593.66% increase from fiscal 2017.
- INMUNE BIO INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2017 was $199.56K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2021-06-30 | $769.00K 10-Q · filed 2021-08-04 | $1.67M derived: sum of 2 quarters · filed 2021-08-04 | |||
| 2021-03-31 | $899.00K 10-Q · filed 2021-08-04 | ||||
| 2020-12-31 | $3.11M 10-K · filed 2021-03-04 | ||||
| 2020-09-30 | $1.05M 10-Q · filed 2020-11-05 | $1.73M derived: sum of 2 quarters · filed 2021-08-04 | $2.41M derived: sum of 3 quarters · filed 2021-08-04 | ||
| 2020-06-30 | $681.00K 10-Q · filed 2021-08-04 | $681.71K 10-Q · filed 2020-08-05 | $1.36M derived: sum of 2 quarters · filed 2021-08-04 | ||
| 2020-03-31 | $682.00K 10-Q · filed 2021-08-04 | $681.71K 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | $4.10M 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | $974.70K 10-Q · filed 2020-11-05 | $1.95M derived: sum of 2 quarters · filed 2020-11-05 | $2.92M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $974.70K 10-Q · filed 2020-11-05 | $1.95M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $974.70K 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $5.38M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $979.56K 10-Q · filed 2019-11-08 | $1.96M derived: sum of 2 quarters · filed 2019-11-08 | $4.42M derived: sum of 3 quarters · filed 2019-11-08 | ||
| 2018-06-30 | $979.56K 10-Q · filed 2019-11-08 | $3.44M derived: sum of 2 quarters · filed 2019-11-08 | |||
| 2018-03-31 | $2.46M 10-Q · filed 2019-11-08 | ||||
| 2017-12-31 | $199.56K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |